You are here

Articles

2013 European Group for Blood and Marrow Transplantation (EBMT) conference London

published: 10 September 2012

Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-Phase CML With T315I Mutation

published: 10 September 2012

Ariad Prepares for Early Launch of CML Drug Ponatinib The Pink Sheet Daily. 2012 Aug 6, E Hayes

published: 10 September 2012

Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells

published: 10 September 2012

Brian Druker: My Vision for CML and the Road to a Cure

published: 21 August 2012

Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration

published: 16 August 2012

New Data Confirm Safety of Stopping Imatinib in CML

published: 30 July 2012

ARIAD Announces Initiation of Randomized Phase 3 Trial of Ponatinib in Newly Diagnosed CML

published: 30 July 2012

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

published: 6 July 2012

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

published: 3 July 2012

EHA 2012: Conference

published: 3 July 2012

Imatinib Mesylate Discontinuation in Patients With CML Treated with Front-Line IM Therapy and Achieved Complete Molecular Response

published: 25 June 2012

ASCO 2012:

published: 11 June 2012

The expanding options for front-line treatment in patients with newly diagnosed CML

published: 26 May 2012

Minimal Residual Disease

published: 10 May 2012

My Approach to Chronic Myeloid Leukemia Interview by L Scott Zoeller. 2012 Apr 3, Tim Hughes, MD

published: 3 May 2012

Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia

published: 3 May 2012

The CMLSg will not appeal the NICE FAD which refuses recommendation of dasatinib for first line use in CML.

published: 15 April 2012

Welcome to cmlsupport.org.uk

published: 29 March 2012

CMLSg's comment on FAD: 1st line use of dasatinib, nilotinib, imatinib. CMLSg will not appeal this FAD.

published: 23 March 2012